We compared the cost‐utility analysis for edoxaban at both doses with that of dabigatran at
both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants …

Background To undertake an economic evaluation of rivaroxaban relative to the standard of
care for stroke prevention in patients with non-valvular atrial fibrillation (AF) in Greece …

Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …

Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …

Objective: The aim of this study was to evaluate, from the Spanish National Health System
perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol …

Background Stroke prevention is complicated in patients with atrial fibrillation (AF) and
coronary artery disease (CAD). We compared the risk of major bleeding among Japanese …

Background Although randomized controlled trials (RCTs) indicated that standard dose non–
vitamin K antagonist oral anticoagulants (NOACs) were more compelling, low dose NOACs …

Atrial fibrillation (AF) is the most prevalent arrhythmia and is associated with an increased
risk of ischemic stroke (IS) and systemic embolism (SE). Stroke prevention is a key element …

Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …